RxDoctor Payments Data

Tiffany Osborne, NP

Psychiatric/Mental Health · Gardner, MANPI 1932748480

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 24 payments — averaging $41.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$467
  • Neurocrine Biosciences, Inc.$110
  • Teva Pharmaceuticals USA, Inc.$107
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$72
  • E.r. Squibb & Sons, L.L.C.$65
  • UCB, Inc.$61
  • plus $124 from 4 others

What the payments were for

  • Food & beverage$95795%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,005 in reported general payments places this provider in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$31,095
Medicare patients
47
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxcarbazepine37$2,672
Duloxetine Hcl78$2,066
Quetiapine Fumarate138$2,046
Clozapine59$1,937
Chlorpromazine Hcl16$1,834
Buspirone Hcl54$1,504
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$996
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine31$902
Venlafaxine Hcl ErVenlafaxine Hcl29$801
Methylphenidate Hcl27$760
Lamotrigine79$760
Bupropion XlBupropion Hcl32$733
Sertraline Hcl72$707
Olanzapine29$683
Hydroxyzine Hcl39$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$44$68329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Gardner

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →